HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Toshio Miyata Selected Research
Toshio Miyata Research Topics
Disease
32
Hypoxia (Hypoxemia)
04/2018 - 12/2003
16
Diabetic Nephropathies (Diabetic Nephropathy)
01/2016 - 01/2002
15
Fibrosis (Cirrhosis)
02/2021 - 10/2001
14
Hypertension (High Blood Pressure)
11/2021 - 05/2003
14
Obesity
11/2021 - 12/2005
13
Inflammation (Inflammations)
04/2020 - 05/2003
11
Proteinuria
03/2015 - 10/2001
10
Hyperglycemia
01/2016 - 12/2003
8
Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2021 - 06/2005
8
Thrombosis (Thrombus)
10/2021 - 10/2001
8
Chronic Renal Insufficiency
01/2017 - 07/2004
7
Cardiovascular Diseases (Cardiovascular Disease)
10/2021 - 02/2008
6
Insulin Resistance
11/2021 - 04/2008
6
Neoplasms (Cancer)
02/2021 - 04/2008
6
Schizophrenia (Dementia Praecox)
01/2021 - 06/2010
6
Chronic Kidney Failure (Chronic Renal Failure)
10/2020 - 01/2002
6
Body Weight (Weight, Body)
01/2020 - 12/2005
6
Ischemia
08/2012 - 12/2005
5
Hemorrhage
10/2017 - 05/2010
4
Albuminuria
01/2016 - 04/2008
4
Renal Insufficiency (Renal Failure)
01/2013 - 10/2003
4
Hyperinsulinism (Hyperinsulinemia)
02/2010 - 04/2008
4
Uremia
09/2005 - 10/2001
3
Psychotic Disorders (Schizoaffective Disorder)
11/2021 - 01/2011
3
Type 2 Diabetes Mellitus (MODY)
04/2018 - 04/2008
3
Polycythemia (Erythrocytosis)
08/2015 - 02/2010
3
Thrombotic Microangiopathies
03/2015 - 10/2001
3
Anemia
10/2013 - 10/2001
3
Nephritis
05/2013 - 12/2005
3
Kidney Diseases (Kidney Disease)
01/2012 - 02/2006
2
BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2022 - 01/2021
2
Hyperlipidemias (Hyperlipidemia)
11/2021 - 01/2010
2
Non-alcoholic Fatty Liver Disease
12/2018 - 10/2017
2
Multiple Sclerosis
04/2018 - 01/2015
2
Alzheimer Disease (Alzheimer's Disease)
01/2018 - 08/2002
2
Cardiomegaly (Heart Hypertrophy)
01/2017 - 11/2013
2
Diabetic Retinopathy (Retinopathy, Diabetic)
03/2015 - 12/2012
Drug/Important Bio-Agent (IBA)
28
Advanced Glycation End Products
IBA
04/2018 - 08/2002
23
Plasminogen Activator Inhibitor 1
IBA
11/2021 - 04/2008
18
Plasminogen Activators (Plasminogen Activator)
IBA
06/2022 - 05/2010
14
Proteins (Proteins, Gene)
FDA Link
03/2015 - 01/2002
11
Glucose (Dextrose)
FDA Link
Generic
11/2021 - 04/2003
11
5- chloro- 2- (((2- (4- (diphenylmethyl)piperazin- 1- yl)- 2- oxoethoxy)acetyl)amino)benzoate
IBA
10/2020 - 05/2010
9
TM5441
IBA
01/2021 - 11/2013
9
Pharmaceutical Preparations
IBA
01/2021 - 05/2003
8
Oxygen (Dioxygen)
IBA
08/2015 - 01/2008
8
Antihypertensive Agents (Antihypertensives)
IBA
04/2010 - 05/2003
7
pentosidine
IBA
01/2018 - 10/2001
7
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
IBA
02/2014 - 10/2001
6
Enzymes
IBA
11/2021 - 05/2003
5
Biomarkers (Surrogate Marker)
IBA
11/2021 - 09/2009
5
Transcription Factors (Transcription Factor)
IBA
04/2018 - 11/2005
5
Insulin (Novolin)
FDA Link
11/2017 - 05/2003
5
Erythropoietin
FDA Link
02/2016 - 10/2001
5
Messenger RNA (mRNA)
IBA
01/2016 - 09/2008
4
Vitamin B 6
IBA
01/2021 - 06/2010
4
Collagen
IBA
10/2020 - 01/2012
4
Plasminogen Inactivators
IBA
02/2016 - 05/2010
4
Prolyl Hydroxylases (Prolyl Hydroxylase)
IBA
02/2016 - 12/2009
4
Luciferases
IBA
01/2015 - 05/2006
4
Elements
IBA
01/2015 - 12/2004
4
Receptor for Advanced Glycation End Products
IBA
03/2014 - 07/2004
4
Nitric Oxide Synthase (NO Synthase)
IBA
11/2013 - 10/2001
4
Lipids
IBA
10/2013 - 04/2008
4
Pyruvaldehyde (Methylglyoxal)
IBA
04/2013 - 04/2003
4
olmesartan
IBA
10/2009 - 05/2003
3
Sugars
IBA
11/2021 - 12/2018
3
Intercellular Signaling Peptides and Proteins (Growth Factors)
IBA
10/2020 - 10/2001
3
Cytokines
IBA
01/2020 - 01/2012
3
Pyridoxamine
IBA
04/2018 - 01/2016
3
Streptozocin (Streptozotocin)
FDA Link
01/2016 - 05/2006
3
NG-Nitroarginine Methyl Ester (L-NAME)
IBA
01/2015 - 10/2001
3
Albumins
IBA
01/2014 - 03/2008
3
Lactoylglutathione Lyase
IBA
07/2013 - 04/2009
3
Salts
IBA
04/2013 - 08/2007
3
8-Hydroxy-2'-Deoxyguanosine
IBA
04/2013 - 01/2002
3
Angiotensin II
IBA
08/2012 - 01/2007
3
Transforming Growth Factor beta (TGF-beta)
IBA
01/2010 - 04/2008
3
Angiotensin II Type 1 Receptor Blockers
IBA
09/2009 - 05/2003
3
1- (5- hydroxy- 3- methyl- 1- phenyl- 1H- pyrazol- 4- yl)- 6- methyl- 1,3- dihydrofuro(3,4- c)pyridine- 7- ol
IBA
08/2009 - 12/2007
3
Angiotensin Receptor Antagonists
IBA
12/2008 - 05/2004
3
Cobalt
IBA
11/2008 - 12/2005
3
Serine Proteinase Inhibitors (Serine Protease Inhibitors)
IBA
09/2008 - 01/2002
3
Tunicamycin
IBA
05/2008 - 12/2005
2
Sucrose (Saccharose)
IBA
11/2021 - 01/2016
2
Urokinase-Type Plasminogen Activator (Urokinase)
FDA Link
01/2020 - 01/2012
2
N(6)-carboxymethyllysine (carboxymethyllysine)
IBA
04/2018 - 10/2001
2
Amino Acids
FDA Link
04/2018 - 10/2003
2
Valsartan (Vals)
FDA Link
04/2018 - 09/2009
2
Therapeutic Uses
IBA
10/2017 - 11/2016
2
Apolipoproteins E (ApoE)
IBA
05/2017 - 10/2014
2
Syntex adjuvant formulation
IBA
01/2017 - 03/2015
2
Fibrinolysin
FDA Link
01/2016 - 09/2008
2
Protein Isoforms (Isoforms)
IBA
08/2015 - 10/2001
Therapy/Procedure
8
Therapeutics
10/2020 - 06/2005
4
Oral Administration
04/2020 - 12/2007
4
Caloric Restriction
11/2008 - 06/2005
2
Fat-Restricted Diet (Diet, Fat Restricted)
01/2021 - 01/2010
2
Peritoneal Dialysis
10/2020 - 09/2005
2
Injections
04/2020 - 06/2004